Novel mTORC1 Inhibitors Kill Glioblastoma Stem Cells

• Main Authors: Jose A. Sandoval (Author), Alexey Tomilov (Author), Sandipan Datta (Author), Sonia Allen (Author), Robert O'Donnell (Author), Thomas Sears (Author), Kevin Woolard (Author), Dmytro Kovalskyy (Author), James M. Angelastro (Author), Gino Cortopassi (Author)
• Format: Book
• Published: MDPI AG, 2020-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Glioblastoma (GBM) is an aggressive tumor of the brain, with an average post-diagnosis survival of 15 months. GBM stem cells (GBMSC) resist the standard-of-care therapy, temozolomide, and are considered a major contributor to tumor resistance. Mammalian target of rapamycin Complex 1 (mTORC1) regulat...